Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 13Unknown 4Withdrawn 3Terminated 3Recruiting 3Active not recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1

Conditions

Vasculitis 1Urogenital Neoplasms 1Stroke 1Lung Neoplasms 1Inflammation 1Depressive Disorder, Major 1Depression 1Colitis 1Cognitive Dysfunction 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Infliximab × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT02638701 2025-07-08

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

University of California, San Francisco

Phase 1/2 Recruiting
8 enrolled

Aneurysm, Vasculitis, Stroke

NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡